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Abstract 
 
Rationale Lymphangioleiomyomatosis (LAM) is characterised by lung cysts and airflow 
obstruction. Matrix metalloproteinases (MMPs) have been implicated in lung destruction 
in LAM. We performed a randomised, double blind trial, comparing the MMP inhibitor 
doxycycline with placebo on the progression of LAM.  
Methods Twenty three women with LAM were randomised to doxycycline 100mg daily 
for three months followed by 200mg daily for 21 months, or matched placebo. Lung 
function, exercise capacity, quality of life and MMP levels were measured.  
Main results Twenty one patients completed 6 months treatment, 17 completed 1 year 
and 15 completed 2 years. Four withdrew due to pneumothorax and four for other 
reasons. Mean decline in FEV1, the primary endpoint, did not differ between the groups 
being -90 (SD 154) ml/year in the placebo group and -123 (246) ml/year in the 
doxycycline group (difference -32.5, 95% C.I. -213 to 148, p=0.35). Doxycycline had no 
effect upon vital capacity, gas transfer, shuttle walk distance or quality of life. Urine 
MMP-9 measurements were lower with doxycycline treatment (p=0.03).  
Conclusions Although with limited numbers we cannot completely exclude an effect of 
doxycycline, the lack of effect on any outcome makes it unlikely that doxycycline has a 
useful effect in LAM. 
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Introduction 
Lymphangioleiomyomatosis (LAM), a rare disease of the lungs and lymphatics which 
occurs almost exclusively in women, can occur as a sporadic disease or in patients with 
tuberous sclerosis complex (TSC). Pulmonary symptoms generally dominate the clinical 
picture as lung cysts form, causing pneumothorax, airflow obstruction and progressive 
respiratory impairment.[1] The rate of disease progression varies considerably between 
patients, with the decline in FEV1 usually being between 70 and 140 ml/yr.[2-4] 
Lymphatic obstruction can lead to chylous pleural effusions, ascites and abdomino-pelvic 
masses and around half of patients have renal angiomyolipomas, a benign mesenchymal 
tumour.[1] 
In patients with LAM the lungs and lymphatics are infiltrated by LAM cells, a clonal cell 
population with bi-allelic inactivation of the TSC-2 gene leading to constitutive activation 
of mTOR.[5] Targeting mTOR with sirolimus in patients with LAM has been shown to 
reduce the decline in FEV1 and angiomyolipoma volume.[4, 6, 7]  
LAM cells produce proteolytic enzymes which may contribute to lung cyst formation.[8, 
9] Matrix metalloproteinases (MMPs) can degrade extra-cellular matrix, and can affect 
cell growth, invasion, angiogenesis and inflammation.[10] MMP-2 and -9 are 
overexpressed in the serum of women with LAM [11, 12] and MMPs -1, -2, -9 and -14 
are strongly expressed in the lungs of patients, particularly adjacent to cysts where 
disrupted collagen and elastic fibres are seen.[13, 14] Inhibition of MMP activity could 
therefore reduce lung destruction in LAM.  
Doxycycline, a tetracycline antibiotic, inhibits the production and activity of several MMPs 
including MMP-1, -2 and -9, and it has reduced pathological tissue remodelling in models 
of vascular disease and tumour growth.[15, 16] Doxycycline is the only MMP inhibitor 
licensed for clinical use and Moses et. al. described a large improvement in spirometry 
and oxygenation in a patient with advanced LAM following treatment with 
doxycycline.[17] In an observational study of patients with mild LAM, doxycycline was 
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associated with a reduction in urine MMP-9 and a relatively slow decline in mean FEV1 of 
70 ml over 12 months.[18, 19] As a consequence of these reports, some women with 
LAM have been taking doxycycline off label. In order to determine if doxycycline could 
inhibit MMP activity and reduce lung destruction in LAM, we conducted a randomised 
study of doxycycline and placebo over two years, using rate of decline in FEV1 (FEV1) as 
the primary outcome measure. Other physiological measures, quality of life, MMP 
activity, safety and tolerability were also recorded. 
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Methods 
Study protocol 
Patients were eligible for the study if they were over 18 years and had sporadic or TSC 
associated LAM, classified as ‘definite’ by European Respiratory Society criteria,[20] and 
an FEV1 below 80% predicted or evidence of a 20% deterioration in FEV1.  Patients were 
excluded if they were post lung transplant or if they had used mTOR inhibitors or had 
had a pneumothorax, chylous effusion or bleeding angiomyolipoma within the previous 
three months. Hormone and bronchodilator treatment for LAM was allowed providing 
treatment had not changed in the three months prior to enrolment. The study was 
approved by the Trent Multicentre Research Ethics committee (NRES 07/H0403/165) the 
Medicines and Healthcare Regulatory Agency (MHRA 03057/0032/001-002) and 
registered with the EU Clinical Trials Registry (EUDRACT 2007-003745-32). All patients 
provided informed consent. 
Patients had a medical history and physical examination and completed a St Georges 
Respiratory Questionnaire (SGRQ) at baseline. Pulmonary function tests including post 
bronchodilator spirometry, gas transfer, lung volumes and endurance shuttle walk test 
were measured according to ARTP/BTS standards in a single laboratory.[21] Blood was 
drawn for haematology, biochemistry, liver function, C reactive protein and blood and 
urine for analysis of MMPs and other biomarkers.  
Patients were randomised to receive either doxycycline 100mg daily or matched placebo 
as a single tablet. After 3 months the dose was increased to two tablets of the active 
drug (200mg doxycycline) or placebo. Patients were assessed every three months over 
two years. At 12 and 24 months, patients had a full evaluation as at baseline (figure 1). 
A CT scan of the thorax and abdomen was carried out at 0 and 24 months in patients 
giving additional consent. The longest dimension of the largest renal angiomyolipoma 
was measured by a radiologist (MK) as described.[7] Patients were withdrawn from the 
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study if there was a fall in FEV1 from study baseline of more than 300ml on two 
consecutive visits or other severe adverse event. Those experiencing pneumothorax 
were also withdrawn from the study, as spirometry can take many months to return to 
baseline following pneumothorax (unpublished data). The full protocol is available in the 
on line supplement. 
MMP and VEGF-D measurements 
Serum total MMPs and vascular endothelial growth factor-D (VEGF-D) were measured 
using a Quantikine MMP-2 Immunoassay, Duoset Human MMP-9 Immunoassay and 
Human VEGF-D ELISA respectively (all from R&D Systems, Minneapolis, MN). Since 
MMPs are secreted as inactive zymogens which require proteolytic cleavage for 
activation, we measured pro and activated MMP-9 in serum and urine using gelatin 
zymography as described.[12, 22]  
Analyses 
The primary outcome was rate of decline in post bronchodilator FEV1 over the course of 
the study [FEV1] analysed on an intention to treat basis on all patients. FEV1 was 
calculated by fitting a regression line to all post bronchodilator FEV1 measurements for 
each patient with the slope of this line expressed in ml/yr. The effect of loss to follow up 
was examined by comparing FEV1 between groups who only completed 6, 12, 18 and 
24 months of treatment. For all endpoints Normality was assessed by Kolmogorov-
Smirnov statistic and mean values for the two groups were compared by two sample t-
test. Analyses were performed in Graphpad Prism version 5.00, (GraphPad Software, 
San Diego California USA). Serum and urine MMP values were compared as log 
transformed values over time between treatment groups using a linear, mixed model, 
with repeated measures from individuals as a random effect in Stata 11 (Timberlake 
Consultants, London, UK). 
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Results 
Patient recruitment and baseline characteristics 
Patients were recruited over a two year period starting in May 2009. After contacting 
149 patients with LAM in the UK, 30 of those responding appeared to be suitable and 
were screened, of whom 23 were eligible. Twelve were assigned to take doxycycline and 
11 to take matched placebo (figure 2). At recruitment the mean age of patients was 46 
years and symptoms had been present for an average of 13.5 years.  Eighteen (78%) 
patients had had a pneumothorax in the past and 13 (56%) had or had had an 
angiomyolipoma. A third of patents were post menopausal. One patient had tuberous 
sclerosis complex and the remainder sporadic LAM. Twenty one of the 23 patients had a 
serum VEGF-D level greater than the figure of 800 pg/ml considered diagnostic for LAM. 
[23] Patients had moderate to severe airflow obstruction with a mean FEV1 of 1.69 l 
(58% predicted) and moderately impaired gas transfer of 4.38 kPa/min/ml (51% 
predicted). Baseline characteristics within the two groups were similar in terms of age, 
disease duration, clinical manifestations, menopausal status, quality of life and serum 
VEGF-D but mean FEV1 and TLCO were slightly lower in the doxycycline group (tables 1 
and E1).  
Effect of doxycycline on rate of decline of FEV1  
Rate of decline in FEV1 (FEV1) analysed on an intention to treat basis was -90.3 (SD 
154) ml/yr in the placebo group and -123 (246) in the doxycycline group; the difference, 
-32.5 ml/yr (95%CI -213 to 147.8), was not significant (p=0.35, figure 3). Patients not 
completing the study had a greater decline in FEV1 (figure 4). Mean FEV1 was -36.3 (SD 
63) ml/year for all patients completing the study and -240 (302) for those stopping early 
for any reason (p=0.049): median values were -30 ml/yr and -162 ml/yr respectively. A 
sensitivity analysis showed there was no difference between doxycycline and placebo for 
any duration of treatment for the primary endpoint (table 2). 
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Secondary endpoints 
Patients treated with doxycycline showed a 150ml rise in FVC after 12 months compared 
with placebo treatment, although no difference was present at 24 months. Otherwise, 
there were no differences between change in TLCO, shuttle walk distance or in quality of 
life scores between the two groups after 12 or 24 months of treatment (table 3). VEGF-D 
did not change significantly in either group over the course of the study (table 3). 
Twenty patients underwent CT scanning of the chest and abdomen at baseline and 13 
had a further scan at the end of the study. No LAM related complications including 
chylous collections developed during the study in any patient. A follow up renal scan in 
six patients receiving placebo and six receiving doxycycline showed no change in mean 
angiomyolipoma size in either group (figure E1). 
Adverse events 
Adverse events were reported on all patients. Six patients were withdrawn because of 
adverse events. In four this was due to a pneumothorax, (one doxycycline, three 
placebo), in one patient to a fall in FEV1 of greater than 300ml (doxycycline) and one 
patient receiving doxycycline had an epileptic seizure and was found to have a 
meningioma (figure 2). Three patients in the placebo group and three in the doxycycline 
group had at least one respiratory infection requiring antibiotic treatment over the study 
period, with two patients in the doxycycline group having several respiratory infections 
(table 4). Although more adverse events were reported with doxycycline, only dyspepsia 
and photosensitivity were attributed to the drug. No significant disturbances in 
haematologic or biochemical values occurred in either group. 
Effect of doxycycline on serum and urine MMPs 
At baseline MMP-2 and MMP-9 were present in serum on gelatin zymography (figure 5), 
and mean total serum MMP-2 and MMP-9 levels, measured by ELISA, were 259 (SD 48) 
and 265 (173) ng/ml respectively. In urine, MMP-9 dimers, neutrophil gelatinase-
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associated lipocalin (NGAL) bound MMP-9, pro-MMP-9 and active MMP-9 were found, but 
not MMP-2 (figure 5).  
There was no significant difference in serum MMP-2 or -9 between groups over the 2 
year period (figure E3). Urine total and active MMP-9 values varied markedly between 
subjects at baseline and within subjects during the study in patients receiving placebo. 
This variation did not relate to infections as assessed clinically or by CRP and neutrophil 
counts (figure 5 and E4). There was a significant reduction in total urinary MMP-9 
(p=0.03) and a reduction of borderline significance in active MMP-9 (p=0.07) in the 
doxycycline group when compared with placebo values over the 2 year period (figure 5).  
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Discussion 
We have conducted the first randomised, placebo controlled trial of doxycycline as a 
potential therapy for LAM. Doxycycline had no effect on the rate of decline of FEV1 over 
two years, and no effect on FVC, TLCO, total lung capacity, shuttle-walk distance or 
quality of life scores after 24 months of treatment. Because LAM is rare, the number of 
patients studied was relatively small. Our findings cannot therefore completely exclude 
an effect of doxycycline, although the lack of a sustained effect on any outcome makes it 
very unlikely that doxycycline has a useful effect that we have missed. 
 
Study subjects were drawn from a national database and a clinical referral service that 
has evaluated over half the patients known to have LAM in the UK. Patients were similar 
to those in other studies, being in their mid-forties, with a disease duration of thirteen 
years and with a similar prevalence of pneumothorax and angiomyolipoma.[24] Patients 
had moderate air-flow obstruction and impairment of gas transfer. Initial power 
calculations suggested we would require 20 patients per group to have 80% power to 
detect a 50% reduction in FEV1. Performing studies in rare diseases is difficult as 
patients need to be from a large area to deliver adequate study power, and only one 
randomised study of LAM has been published to date. Frequent pneumothoraces also 
limit recruitment of patients with LAM. Our recruitment criteria were broad and we linked 
study visits with the patients’ medical care where possible to facilitate participation in the 
study. Performing the study in a single centre ensures that procedures are standardised 
but the need for patients to travel limited recruitment to some extent. A more significant 
issue was that mTOR inhibitor therapy became more widely available during the 
recruitment period and the enlarging evidence base for this therapy limited our ability to 
recruit patients with progressive disease to a placebo controlled study.[6, 25] The study 
was designed to guard against patients with rapidly declining lung function receiving 
placebo for two years by incorporating stopping criteria for patients with a greater than 
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300ml fall in FEV1 as a pre-determined secondary end point. Two patients left the study 
early to receive sirolimus, one after a greater than 300ml fall in FEV1.  
 
In the intention to treat analysis mean FEV1 was -123 ml/year in the doxycycline group 
and -90 ml/year in the placebo group, values in keeping with previous reports. Patients 
who withdrew early had more rapid decline in lung function. The relatively low FEV1 in 
patients completing the study, -35 ml/yr, reflects the fact that patients with more 
aggressive disease were already receiving sirolimus or were opting for it. In addition, 
one third of our study population were post-menopausal when the decline in FEV1 is 
slower which may make it more difficult to show a treatment effect. [2, 3] The 95% CI 
for FEV1 in the patients completing the study were tighter than in the intention to treat 
analysis, despite the smaller numbers, reflecting the fact that more measurements were 
made per patient over a longer period, and these patients had more stable disease. 
Nevertheless there was little difference in mean FEV1 between the two groups (6.1 
ml/yr (95% CI -67 to 79)). A limitation of the study was that, due to chance, patients 
randomised to doxycycline had slightly lower lung function than those receiving placebo. 
Although there is no definitive data on whether lung function varies with disease severity 
in LAM, it is possible that those with more severe disease may decline more rapidly 
although the converse is true in patients with alpha 1-anti-trypsin deficiency. [26]  
 
Two reports have described the effect of doxycycline on lung function. In a single patient 
with severe disease, lung function and oxygenation improved after doxycycline 
treatment although this may have been due treatment of a co-existing infection. [17] In 
a series of 38 patients all treated with doxycycline for 12 months, Pimenta et. al. 
observed that some patients remained stable on treatment and these tended to be those 
with better lung function. A relatively benign clinical course in some patients with LAM is 
well documented, and without a control group the significance of these findings is 
difficult to assess. [27] MMP-2 and -9 are increased in LAM lung tissue,[14] in cells 
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derived from TSC knock-out animals[28] and in the serum and urine of patients with 
LAM,[11] making them attractive candidates for causing the accelerated extra-cellular 
matrix destruction and cyst formation observed.[13, 14, 29] All the MMP measurements, 
but particularly those from urine, showed considerable intra and inter-subject variation 
which was not obviously related to infection. Doxycycline treatment was associated with 
suppression of urinary MMP-9 but not serum MMP-9. Our failure to find a reduction in 
serum MMP-9 contrasts with the 5% reduction seen by Pimenta et. al.[19] and although 
this may reflect our smaller numbers and intra-subject variability, there must be doubt 
as to whether a change of 5% would result in clinical benefit. The lack of efficacy of 
doxycycline in preventing decline in lung function raises questions about the role of 
MMPs in lung destruction in LAM. However, the metalloproteinase system is complex 
with activating proteases and inhibitors interacting to regulate overall MMP activity both 
spatially and temporally. Further studies are required to determine whether MMPs are 
central to lung destruction in LAM and if more potent or selective targeting of individual 
proteases or their substrates could reduce lung destruction.  
 
In summary, we found that treatment with doxycycline for two years had no effect on 
the decline in lung function in patients with LAM. It is common for patients with a rare 
disease to take off-label therapies on the basis of a biologically plausible mechanism of 
action but our findings provide no support to justify using doxycycline to treat LAM. 
Specific targeting of lung destruction in LAM and other chronic lung diseases needs 
better understanding of the pathologic mechanisms involved. 
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Figure legends 
Figure 1. Outline of study protocol. Visit includes history, physical examination, post 
bronchodilator spirometry and safety blood tests. QoL: Quality of life assessment. 
Figure 2. Recruitment and retention of participants. 
Figure 3. Serial post bronchodilator FEV1 for all study participants. 
Figure 4. FEV1 for individual participants compared with time to study withdrawal. 
Patients with more rapid falls in FEV1 were more likely to withdraw from the study. 
Figure 5. (a) Gelatin zymograms of serum and urine from representative patients 
treated with doxycycline or placebo to detect MMP-2 and -9. MMP species are visible as 
white areas of degraded gelatin. rhMMP: recombinant human MMP protein standard. 
NGAL: neutrophil gelatinase associated lipocalin. (b) Mean (+SE) urinary total and active 
MMP-9 throughout the two years of the study. P values are for overall differences 
between treatment groups. 
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Tables 
Table 1. 
Baseline characteristics of study subjects 
 
All patients 
(S.D.) 
Doxycycline 
(S.D.) 
Placebo 
(S.D.) 
n 23 12 11 
Patient characteristics    
Age - yr 46.5 (9.0) 47.0 (9.3) 45.7 (8.9) 
Duration of disease - yr 13.5 (9.1) 14.5 (9.0) 12.5 (9.4) 
Post menopause  8 4 4 
Pneumothorax†  18 9 9 
Angiomyolipoma‡  14 6 8 
TSC-LAM  1 0 1 
Supplemental oxygen use 5 3 2 
Lung function - % predicted    
FEV1  58 (23) 52 (25) 64 (19) 
FVC   95 (22) 97 (26) 92 (18) 
TLCO  51 (21) 45 (21) 57 (20) 
TLC  94 (20) 99 (23) 89 (15) 
Other parameters    
Shuttle walk dist. - m 573 (286) 560 (284) 586 (301) 
SGRQ  - total score 35 (4) 36 (6) 33 (6) 
VEGF-D - pg/ml 2540 (1377) 2347 (1399) 2751 (1387) 
† Number of patients having had at least one pneumothorax. ‡ Number of patients with 
one or more angiomyolipoma at any time.  
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Table 2. 
Sensitivity analysis comparing FEV1 in each group for varying durations of treatment. 
Duration of treatment  n mean FEV1 
ml/yr (SD) 
mean difference 
95% C.I. 
p 
Any 
(ITT analysis) 
Doxycycline 12 -122.8 (246) -32.5 
-213 to 147.8 
0.35 
Placebo 11 -90.3 (154) 
>6 months 
Doxycycline 12 -122.8 (246) -61.3 
-247 to 124 
0.25 
Placebo 9 -61.5 (112) 
>12 months 
Doxycycline 9 -34.4 (81) -7.7 
-76 to 60 
0.41 
Placebo 8 -26.7 (42) 
>18 months 
Doxycycline 8 -33.5 (86) 6.1 
-67 to 79 
0.43 
Placebo 7 -39.6 (24) 
24 months 
Doxycycline 8 -33.5 (86) 6.1 
-67 to 79 
0.43 
Placebo 7 -39.6 (24) 
ITT: intention to treat 
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Table 3. Mean values and change at 12 and 24 months for secondary outcomes.  
 
12 months 24 months 
Doxycycline Placebo 
Mean diff. for 
change 
Dox vs. Pl 
95% C.I. 
p 
 
Doxycycline Placebo 
Mean diff. for 
change 
Dox vs. Pl 
95% C.I. 
p 
 
 
mean 
(SD) 
change 
(SD) 
mean 
(SD) 
change 
(SD) 
mean 
(SD) 
change 
(SD) 
mean 
(SD) 
change 
(SD) 
Number 
completing 
9 8   8 7   
FVC (l) 
3.09 
(0.78) 
0.19 
(0.10) 
3.04 
(0.68) 
0.05 
(0.11) 
0.15 
-0.26 to -0.03 
0.008 
3.05 
(0.83) 
0.05 
(0.18) 
3.09 
(0.74) 
-.004 
(0.11) 
-0.05 
-0.22 to 0.12 
0.24 
TLCO 
(mmol/kPa/min) 
3.83 
(1.98) 
-0.02 
(0.27) 
4.91 
(1.87) 
0.16 
(0.33) 
0.18 
-0.11 to 0.48 
0.11 
4.23 
(2.00) 
-0.04 
(0.56) 
5.31 
(1.47) 
0.08 
(0.48) 
0.11 
-0.47 to 0.69 
0.33 
Shuttle walk 
distance (m) 
617 
(338) 
33 
(145) 
554 
(369) 
-13 
(139) 
-46 
-189 to 97 
0.25 
632 
(340) 
4 
(174) 
630 
(232) 
-1 
(188) 
-5.18 
-207 to197 
0.48 
SGRQ 
symptoms 
 
activity 
 
impact 
 
total score 
 
 
42.2 
(30) 
50.8 
(32.3) 
30.2 
(24.9) 
40.2 
(27.6) 
 
- 0.8 
(16.9) 
-1.7 
(7.5) 
-3.7 
(11.8) 
-3.1 
(9.8) 
 
32.5 
(21.7) 
51.2 
(26.1) 
25.1 
(18.9) 
32.0 
(20.7) 
 
0.48 
(8.6) 
4.7 
(9.7) 
-2.8 
(7.3) 
-0.05 
(4.9) 
 
-1.24 
-15.3 to 12.8 
-5.8 
-14.5 to 2.8 
-0.75 
-10.6 to 9.1 
-3.0 
-11.4 to 5.3 
 
0.43 
 
0.08 
 
0.44 
 
0.22 
 
37.4 
(20.4) 
48.3 
(25.9) 
26.5 
(18.0) 
32.2 
(21.4) 
 
5.0 
(14.7) 
0.78 
(12.2) 
2.1 
(4.9) 
1.7 
(6.9) 
 
35.4 
(25.4) 
51.1 
(22.5) 
22.7 
(11.8) 
31.4 
(16.6) 
 
-7.1 
(19.3) 
7.1 
(8.2) 
0.7 
(5.7) 
1.3 
(4.6) 
 
12.1 
-7.9 to 32.0 
-6.3 
-18.5 to 5.9 
1.2 
-4.5 to 6.9 
0.42 
-6.4 to 7.2 
 
0.11 
 
0.14 
 
0.33 
 
0.45 
VEGF-D 
(pg/ml) 
2135 
(1256) 
-107 
(246) 
2751 
(1387) 
-69 
(981) 
38 
-680 to 756 
0.91 
2229 
(1083) 
-412 
(562) 
2660 
(1427) 
-290 
(849) 
122 
-776 to 1019 
0.77 
SGRQ: St Georges Respiratory Questionnaire. VEGF-D: vascular endothelial growth factor-D. Dox: doxycycline. Pl: placebo. 
P values are for the difference between the changes for doxycycline and placebo at the two time points.
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Table 4.  
Adverse events during study 
Category All 
patients 
Doxycycline 
grade 
Placebo 
grade 
1-2 3-4 1-2 3-4 
Auditory 
Tinnitus* 
 
1 
 
1 
   
Dermatology 
Dry skin 
Flushing+ 
Photosensitive rash 
Bruising 
 
2 
3 
2 
1 
 
1 
2 
1 
1 
  
1 
1 
1 
 
GI 
Diarrhoea 
Dyspepsia 
 
1 
4 
 
1 
4 
   
Infection 
Upper aerodigestive 
 
16 
 
8 
 
2 
 
6 
 
Lymphatics 
Chyle leak (chyloptysis) 
 
1 
 
 
  
1 
 
Neurological  
Neuropathy (motor) 
Carpal tunnel 
Seizure$  
 
1 
1 
1 
 
1 
1 
1 
   
Pain 
Headache 
Musculoskeletal 
 
3 
1 
 
1 
1 
  
2 
 
Respiratory 
Dyspnoea  
FEV1 (fall)  
Pneumothorax 
Bronchospasm 
 
2 
1 
4 
1 
 
1 
1 
1 
1 
  
1 
 
2 
 
 
 
1 
Malignancy 
Meningioma 
 
1 
 
1 
   
Total 45 29 2 15 1 
Adverse events categorised by Common Terminology Criteria for Adverse Events v3.0. No 
grade 5 events were observed. *Patient had tinnitus prior to study, symptoms persisted on 
stopping drug. $In a patient with meningioma. +All patients were approaching the menopause.
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